Lantheus Secures FDA Approval for Pylarify TruVu, Plans Q4 2026 Launch
Summary
Lantheus Holdings has received full FDA approval for its Pylarify TruVu™ (piflufolastat F 18) Injection, a significant milestone for the company. This approval directly supports Lantheus' recently announced strategic pivot towards radiodiagnostics, as detailed in its Q4 and FY25 financial results and 10-K filing. The company expects a phased rollout of Pylarify TruVu to begin in Q4 2026. This development provides market access for a key product in their new strategic focus, validating their R&D efforts and offering a new revenue stream. Traders will now focus on the commercial launch and initial sales performance of Pylarify TruVu.
At the time of this announcement, LNTH was trading at $73.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.7B. The 52-week trading range was $47.25 to $111.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.